{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,1,8]],"date-time":"2026-01-08T00:42:42Z","timestamp":1767832962637,"version":"3.49.0"},"reference-count":37,"publisher":"Elsevier BV","issue":"2","license":[{"start":{"date-parts":[[2018,2,1]],"date-time":"2018-02-01T00:00:00Z","timestamp":1517443200000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2018,2,1]],"date-time":"2018-02-01T00:00:00Z","timestamp":1517443200000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"}],"content-domain":{"domain":["clinicalkey.com","clinicalkey.com.au","clinicalkey.es","clinicalkey.fr","clinicalkey.jp","clinical-lymphoma-myeloma-leukemia.com","elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["Clinical Lymphoma Myeloma and Leukemia"],"published-print":{"date-parts":[[2018,2]]},"DOI":"10.1016\/j.clml.2017.11.009","type":"journal-article","created":{"date-parts":[[2017,12,2]],"date-time":"2017-12-02T04:46:12Z","timestamp":1512189972000},"page":"e115-e121","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":18,"title":["Characterizing Autoimmune Disease-associated Diffuse Large B-cell Lymphoma in a SEER\u2013Medicare Cohort"],"prefix":"10.1016","volume":"18","author":[{"ORCID":"https:\/\/orcid.org\/0000-0003-4414-0489","authenticated-orcid":false,"given":"Jean L.","family":"Koff","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Ashish","family":"Rai","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Christopher R.","family":"Flowers","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"78","reference":[{"key":"10.1016\/j.clml.2017.11.009_bib1","series-title":"GLOBOCAN 2012 v1.0, Cancer Incidence and Mortality Worldwide: IARC CancerBase No. 11 [Internet]","author":"Ferlay","year":"2013"},{"key":"10.1016\/j.clml.2017.11.009_bib2","series-title":"WHO Classification of Tumours of Haematopoietic and Lymphoid Tissues","author":"Swerdlow","year":"2008"},{"key":"10.1016\/j.clml.2017.11.009_bib3","article-title":"US lymphoid malignancy statistics by World Health Organization subtypes [e-pub ahead of print]","author":"Teras","year":"2016","journal-title":"CA Cancer J Clin"},{"key":"10.1016\/j.clml.2017.11.009_bib4","doi-asserted-by":"crossref","first-page":"161","DOI":"10.1002\/ajh.24615","article-title":"Diffuse large B-cell lymphoma with primary treatment failure: ultra-high risk features and benchmarking for experimental therapies","volume":"92","author":"Costa","year":"2017","journal-title":"Am J Hematol"},{"key":"10.1016\/j.clml.2017.11.009_bib5","first-page":"393","article-title":"Improving outcomes for patients with diffuse large B-cell lymphoma","volume":"60","author":"Flowers","year":"2010","journal-title":"CA Cancer J Clin"},{"key":"10.1016\/j.clml.2017.11.009_bib6","doi-asserted-by":"crossref","first-page":"15","DOI":"10.1093\/jncimonographs\/lgu010","article-title":"Medical history, lifestyle, family history, and occupational risk factors for diffuse large B-cell lymphoma: the InterLymph Non-Hodgkin Lymphoma Subtypes Project","volume":"2014","author":"Cerhan","year":"2014","journal-title":"J\u00a0Natl Cancer Inst Monogr"},{"key":"10.1016\/j.clml.2017.11.009_bib7","doi-asserted-by":"crossref","first-page":"2337","DOI":"10.1001\/archinte.165.20.2337","article-title":"The risk of lymphoma development in autoimmune diseases: a meta-analysis","volume":"165","author":"Zintzaras","year":"2005","journal-title":"Arch Intern Med"},{"key":"10.1016\/j.clml.2017.11.009_bib8","doi-asserted-by":"crossref","first-page":"1","DOI":"10.1097\/MD.0b013e31824125e4","article-title":"Prognosis and outcome of non-Hodgkin lymphoma in primary Sj\u00f6gren syndrome","volume":"91","author":"Voulgarelis","year":"2012","journal-title":"Medicine (Baltimore)"},{"key":"10.1016\/j.clml.2017.11.009_bib9","doi-asserted-by":"crossref","first-page":"1507","DOI":"10.1136\/ard.2004.034504","article-title":"Non-Hodgkin's lymphoma in systemic lupus erythematosus","volume":"64","author":"Bernatsky","year":"2005","journal-title":"Ann Rheum Dis"},{"key":"10.1016\/j.clml.2017.11.009_bib10","doi-asserted-by":"crossref","first-page":"4029","DOI":"10.1182\/blood-2007-10-119974","article-title":"Autoimmune disorders and risk of non-Hodgkin lymphoma subtypes: a pooled analysis within the InterLymph Consortium","volume":"111","author":"Ekstr\u00f6m Smedby","year":"2008","journal-title":"Blood"},{"key":"10.1016\/j.clml.2017.11.009_bib11","doi-asserted-by":"crossref","first-page":"692","DOI":"10.1002\/art.21675","article-title":"Association of chronic inflammation, not its treatment, with increased lymphoma risk in rheumatoid arthritis","volume":"54","author":"Baecklund","year":"2006","journal-title":"Arthritis Rheum"},{"key":"10.1016\/j.clml.2017.11.009_bib12","doi-asserted-by":"crossref","first-page":"406","DOI":"10.1093\/aje\/kwu290","article-title":"Associations of non-Hodgkin Lymphoma (NHL) risk with autoimmune conditions according to putative NHL loci","volume":"181","author":"Wang","year":"2015","journal-title":"Am J Epidemiol"},{"key":"10.1016\/j.clml.2017.11.009_bib15","series-title":"International Classification of Diseases for Oncology","author":"Fritz","year":"2013"},{"key":"10.1016\/j.clml.2017.11.009_bib16","series-title":"SEER Program Coding and Staging Manual 2016","author":"Adamo","year":"2016"},{"key":"10.1016\/j.clml.2017.11.009_bib17","doi-asserted-by":"crossref","first-page":"3231","DOI":"10.1002\/cncr.23914","article-title":"Ethnic variations in diagnosis, treatment, socioeconomic status, and survival in a large population-based cohort of elderly patients with non-Hodgkin lymphoma","volume":"113","author":"Wang","year":"2008","journal-title":"Cancer"},{"key":"10.1016\/j.clml.2017.11.009_bib18","doi-asserted-by":"crossref","first-page":"625","DOI":"10.1186\/1471-2407-10-625","article-title":"Racial differences in treatment and survival in older patients with diffuse large B-cell lymphoma (DLBCL)","volume":"10","author":"Griffiths","year":"2010","journal-title":"BMC Cancer"},{"key":"10.1016\/j.clml.2017.11.009_bib19","doi-asserted-by":"crossref","first-page":"1335","DOI":"10.1007\/s00277-014-2048-6","article-title":"Treatment practice in the elderly patient with chronic lymphocytic leukemia-analysis of the combined SEER and Medicare database","volume":"93","author":"Satram-Hoang","year":"2014","journal-title":"Ann Hematol"},{"key":"10.1016\/j.clml.2017.11.009_bib20","doi-asserted-by":"crossref","first-page":"2191","DOI":"10.1200\/JCO.2009.25.4052","article-title":"Chemotherapy and survival benefit in elderly patients with advanced non-small-cell lung cancer","volume":"28","author":"Davidoff","year":"2010","journal-title":"J\u00a0Clin Oncol"},{"key":"10.1016\/j.clml.2017.11.009_bib21","doi-asserted-by":"crossref","first-page":"157","DOI":"10.1016\/j.jgo.2012.12.005","article-title":"A\u00a0novel approach to improve health status measurement in observational claims-based studies of cancer treatment and outcomes","volume":"4","author":"Davidoff","year":"2013","journal-title":"J\u00a0Geriatr Oncol"},{"key":"10.1016\/j.clml.2017.11.009_bib22","doi-asserted-by":"crossref","first-page":"4808","DOI":"10.1182\/blood-2011-04-348367","article-title":"Addition of rituximab to chemotherapy alone as first-line therapy improves overall survival in elderly patients with mantle cell lymphoma","volume":"118","author":"Griffiths","year":"2011","journal-title":"Blood"},{"key":"10.1016\/j.clml.2017.11.009_bib23","doi-asserted-by":"crossref","first-page":"6079","DOI":"10.1002\/cncr.27638","article-title":"Comparative effectiveness and cost of adding rituximab to first-line chemotherapy for elderly patients diagnosed with diffuse large B-cell lymphoma","volume":"118","author":"Griffiths","year":"2012","journal-title":"Cancer"},{"key":"10.1016\/j.clml.2017.11.009_bib24","doi-asserted-by":"crossref","first-page":"613","DOI":"10.1016\/0895-4356(92)90133-8","article-title":"Adapting a clinical comorbidity index for use with ICD-9-CM administrative databases","volume":"45","author":"Deyo","year":"1992","journal-title":"J\u00a0Clin Epidemiol"},{"key":"10.1016\/j.clml.2017.11.009_bib25","doi-asserted-by":"crossref","first-page":"373","DOI":"10.1016\/0021-9681(87)90171-8","article-title":"A\u00a0new method of classifying prognostic comorbidity in longitudinal studies: development and validation","volume":"40","author":"Charlson","year":"1987","journal-title":"J\u00a0Chron Dis"},{"key":"10.1016\/j.clml.2017.11.009_bib26","doi-asserted-by":"crossref","first-page":"268","DOI":"10.3109\/10428194.2012.708751","article-title":"Examining racial differences in diffuse large B-cell lymphoma presentation and survival","volume":"54","author":"Flowers","year":"2013","journal-title":"Leuk Lymphoma"},{"key":"10.1016\/j.clml.2017.11.009_bib27","doi-asserted-by":"crossref","first-page":"1491","DOI":"10.1007\/s10067-006-0532-7","article-title":"Characteristics of patients with systemic lupus erythematosus (SLE) and non-Hodgkin\u2019s lymphoma (NHL)","volume":"26","author":"King","year":"2007","journal-title":"Clin Rheumatol"},{"key":"10.1016\/j.clml.2017.11.009_bib28","doi-asserted-by":"crossref","first-page":"2530","DOI":"10.1002\/cncr.25765","article-title":"Racial differences in the presentation and outcomes of diffuse large B-cell lymphoma in the United States","volume":"117","author":"Shenoy","year":"2011","journal-title":"Cancer"},{"key":"10.1016\/j.clml.2017.11.009_bib29","doi-asserted-by":"crossref","first-page":"378","DOI":"10.1200\/JCO.2010.30.1515","article-title":"Racial differences in chronic immune stimulatory conditions and risk of non-Hodgkin's lymphoma in veterans from the United States","volume":"29","author":"Koshiol","year":"2011","journal-title":"J\u00a0Clin Oncol"},{"key":"10.1016\/j.clml.2017.11.009_bib30","doi-asserted-by":"crossref","first-page":"847","DOI":"10.1053\/berh.2002.0259","article-title":"Epidemiology of systemic lupus erythematosus","volume":"16","author":"Petri","year":"2002","journal-title":"Best Pract Res Clin Rheumatol"},{"key":"10.1016\/j.clml.2017.11.009_bib31","doi-asserted-by":"crossref","first-page":"308","DOI":"10.1191\/0961203306lu2305xx","article-title":"Epidemiology of systemic lupus erythematosus: a comparison of worldwide disease burden","volume":"15","author":"Danchenko","year":"2006","journal-title":"Lupus"},{"key":"10.1016\/j.clml.2017.11.009_bib32","doi-asserted-by":"crossref","first-page":"257","DOI":"10.1016\/j.semarthrit.2008.10.007","article-title":"Understanding the epidemiology and progression of systemic lupus erythematosus","volume":"39","author":"Pons-Estel","year":"2010","journal-title":"Semin Arthritis Rheum"},{"key":"10.1016\/j.clml.2017.11.009_bib33","doi-asserted-by":"crossref","first-page":"503","DOI":"10.1038\/35000501","article-title":"Distinct types of diffuse large B-cell lymphoma identified by gene expression profiling","volume":"403","author":"Alizadeh","year":"2000","journal-title":"Nature"},{"key":"10.1016\/j.clml.2017.11.009_bib34","doi-asserted-by":"crossref","first-page":"4587","DOI":"10.1200\/JCO.2007.15.9277","article-title":"Addition of rituximab to standard chemotherapy improves the survival of both the germinal center B-cell-like and non-germinal center B-cell-like subtypes of diffuse large B-cell lymphoma","volume":"26","author":"Fu","year":"2008","journal-title":"J\u00a0Clin Oncol"},{"key":"10.1016\/j.clml.2017.11.009_bib35","doi-asserted-by":"crossref","first-page":"1937","DOI":"10.1056\/NEJMoa012914","article-title":"The use of molecular profiling to predict survival after chemotherapy for diffuse large-B-cell lymphoma","volume":"346","author":"Rosenwald","year":"2002","journal-title":"N\u00a0Engl J Med"},{"key":"10.1016\/j.clml.2017.11.009_bib36","doi-asserted-by":"crossref","first-page":"3774","DOI":"10.1002\/art.22277","article-title":"Characteristics of diffuse large B cell lymphomas in rheumatoid arthritis","volume":"54","author":"Baecklund","year":"2006","journal-title":"Arthritis Rheum"},{"key":"10.1016\/j.clml.2017.11.009_bib37","doi-asserted-by":"crossref","first-page":"87","DOI":"10.3816\/CLM.2008.n.009","article-title":"Incidence of lymphoma in patients with rheumatoid arthritis: a systematic review of the literature","volume":"8","author":"Kaiser","year":"2008","journal-title":"Clin Lymphoma Myeloma"},{"key":"10.1016\/j.clml.2017.11.009_bib38","doi-asserted-by":"crossref","first-page":"2275","DOI":"10.1001\/jama.295.19.2275","article-title":"Anti-TNF antibody therapy in rheumatoid arthritis and the risk of serious infections and malignancies: systematic review and meta-analysis of rare harmful effects in randomized controlled trials","volume":"295","author":"Bongartz","year":"2006","journal-title":"JAMA"},{"key":"10.1016\/j.clml.2017.11.009_bib39","doi-asserted-by":"crossref","first-page":"400","DOI":"10.1136\/ard.2009.117762","article-title":"Lymphoma in patients treated with anti-TNF: results of the 3-year prospective French RATIO registry","volume":"69","author":"Mariette","year":"2010","journal-title":"Ann Rheum Dis"}],"container-title":["Clinical Lymphoma Myeloma and Leukemia"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S2152265017308856?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S2152265017308856?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2025,10,31]],"date-time":"2025-10-31T00:29:36Z","timestamp":1761870576000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S2152265017308856"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2018,2]]},"references-count":37,"journal-issue":{"issue":"2","published-print":{"date-parts":[[2018,2]]}},"alternative-id":["S2152265017308856"],"URL":"https:\/\/doi.org\/10.1016\/j.clml.2017.11.009","relation":{},"ISSN":["2152-2650"],"issn-type":[{"value":"2152-2650","type":"print"}],"subject":[],"published":{"date-parts":[[2018,2]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"Characterizing Autoimmune Disease-associated Diffuse Large B-cell Lymphoma in a SEER\u2013Medicare Cohort","name":"articletitle","label":"Article Title"},{"value":"Clinical Lymphoma Myeloma and Leukemia","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.clml.2017.11.009","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2017 Elsevier Inc. All rights reserved.","name":"copyright","label":"Copyright"}]}}